- Home
- LPCN vs CLRB Comparison
LPCN vs CLRB Comparison
Compare LPCN & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- CLRB
- Stock Information
- Founded
- LPCN 1997
- CLRB 2002
- Country
- LPCN United States
- CLRB United States
- Employees
- LPCN N/A
- CLRB N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- CLRB Health Care
- Exchange
- LPCN Nasdaq
- CLRB Nasdaq
- Market Cap
- LPCN 16.1M
- CLRB 17.6M
- IPO Year
- LPCN N/A
- CLRB N/A
- Fundamental
- Price
- LPCN $3.00
- CLRB $4.78
- Analyst Decision
- LPCN Strong Buy
- CLRB Hold
- Analyst Count
- LPCN 2
- CLRB 2
- Target Price
- LPCN $9.00
- CLRB N/A
- AVG Volume (30 Days)
- LPCN 29.3K
- CLRB 166.2K
- Earning Date
- LPCN 08-07-2025
- CLRB 08-12-2025
- Dividend Yield
- LPCN N/A
- CLRB N/A
- EPS Growth
- LPCN N/A
- CLRB N/A
- EPS
- LPCN N/A
- CLRB N/A
- Revenue
- LPCN $3,674,834.00
- CLRB N/A
- Revenue This Year
- LPCN N/A
- CLRB N/A
- Revenue Next Year
- LPCN N/A
- CLRB N/A
- P/E Ratio
- LPCN N/A
- CLRB N/A
- Revenue Growth
- LPCN N/A
- CLRB N/A
- 52 Week Low
- LPCN $2.68
- CLRB $4.36
- 52 Week High
- LPCN $7.61
- CLRB $94.50
- Technical
- Relative Strength Index (RSI)
- LPCN 40.07
- CLRB 33.97
- Support Level
- LPCN $3.10
- CLRB $4.62
- Resistance Level
- LPCN $3.39
- CLRB $5.17
- Average True Range (ATR)
- LPCN 0.18
- CLRB 0.74
- MACD
- LPCN -0.00
- CLRB -0.19
- Stochastic Oscillator
- LPCN 0.00
- CLRB 7.20
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.